Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris. Issue 7 (2nd July 2020)

• Record Type: Journal Article
• Authors: Yang, Zhijian; Gao, Fan; Wang, Xiaoliang; Shi, Likang; Zhou, Zheng; Jiang, Yuanxiang; Ma, Xinxing; Zhang, Chao; Zhou, Chenliang; Zeng, Xianfang; Liu, Ge; Fan, Jiang; Mao, Qunying; Shi, Li
• Is Part Of: Human vaccines & immunotherapeutics. Volume 16:Issue 7(2020)
• Page Start: 1602
• Page End: 1610
• Publication Date: 2020-07-02
• Subjects: Enterovirus 71 -- hand foot and mouth disease -- vaccine -- immunogenicity -- Pichia pastoris -- virus-like particles; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2019.1649554
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Enterovirus 71 (EV71) is one of the major causative agents for hand, foot and mouth disease (HFMD) in children. Although there are three inactivated virus-based HFMD vaccines licensed in China, alternative approaches have been taken to produce an effective and safer vaccine that is easier to manufacture in large scale. Among these, a virus-like particles (VLPs) based EV71 vaccine is under active development. For this purpose, an efficient methodology for the production of EV71-VLPs by recombinant technology is needed. We here report the construction and expression of the P1 and 3C genes of EV71 in Pichia pastoris for producing VLP-based EV71 vaccine antigen with a high yield and simple manufacturing process. Based on codon-optimized P1 and 3C genes, EV71-VLPs were efficiently expressed in Pichia pastoris system, and the expression level reached 270 mg/L. Biochemical and biophysical analyses showed that the produced EV71-VLPs consisted of processed VP0, VP1, and VP3 present as ~35nm spherical particles. The immune response as a function of EV71-VLPs and adjuvant dose ratio was investigated for vaccine development. Immunization with EV71-VLPs of 1–5 µg/dose and adjuvant of 225 µg/dose induced robust neutralizing antibody responses in mice and provided effective protection against lethal challenge in both maternally transferred antibody and passive transfer protection mouse models. Therefore, the yeast produced EV71-VLPs antigen is a promising candidate for the development of a vaccine against HFMD.